DocWire News Editors

DocwireNews

Once-daily ibrutinib and rituximab (IR) was superior to placebo and rituximab in terms of prolonging progression-free survival (PFS) and providing sustained hemoglobin improvements in patients with symptomatic Waldenstrom&rsquo;s macroglobulinemia (WM), according to 5-year follow-up data from the phase 3 iNNOVATE trial presented at the 62nd American Society of Hematology Annual Meeting and Exposition.The study, which was presented by Christian Buske, MD, of the University Hospital of Ulm in Germany, randomly assigned patients with confirmed symptomatic WM to either once-daily ibrutinib 420 mg with rituximab (n=75) or placebo plus rituximab (n=75). The endpoints of the study were PFS and response rates, overall survival (OS), hemoglobin improvement, and safety.Over a median follow-up period of 50 months, the median PFS in the IR arm had not been reached, whereas the median PFS in the placebo and rituximab arm was 20.3 months (p&lt;0.0001). At the 54-month landmark timepoint, the PFS rates for IR as well as rituximab with placebo were 68% and versus 25%, respectively.The PFS benefit with IR versus placebo plus rituximab was observed in patients who were both treatment na&iuml;ve and patients who were previously treated. Additionally, the PFS benefit with IR was observed across patient subgroups including baseline age, sex, serum immunoglobulin, hemoglobin, and International Prognostic Scoring System for Waldenstr&ouml;m Macroglobulinemia.A significantly greater proportion of major responses were observed in the IR arm (76% vs. 31%; p&lt;0.0001). The overall response rates were 92% in the IR group versus 44% in the placebo arm (p&lt;0.0001).In addition, more patients who received IR experienced sustained hemoglobin improvements (77% vs. 43%; p&lt;0.0001). The median OS was not reached in either arm, but the OS rates at the 54-month landmark timepoint were 86% with IR compared with 84% with rituximab and placebo.The most common grade 3/4 adverse events in the study population included atrial fibrillation (AF), hypertension, neutropenia, and anemia. Approximately 75% of the 12 patients with grade 3/4 AF remained on treatment, and up to 45% of patients remained on treatment at time of study closure.<a href="https://ash.confex.com/ash/2020/webprogram/Paper134460.html">https://ash.confex.com/ash/2020/webprogram/Paper134460.html</a>

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

Ibrutinib Prolongs PFS, Leads to Sustained Hemoglobin Improvements in Patients With Waldenstrom’s Macroglobulinemia

ASH Annual Meeting 2020

Once-daily ibrutinib and rituximab (IR) was superior to placebo and rituximab in terms of prolonging progression-free survival (PFS) and providing sustained hemoglobin ...

Ibrutinib Prolongs PFS, Leads to Sustained Hemoglobin Improvements in Patients With Waldenstrom’s

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe